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Abstract
Specific intestinal microbiota has been shown to induce Foxp3
+ regulatory T cell development. However, it remains unclear
how development of another regulatory T cell subset, Tr1 cells, is regulated in the intestine. Here, we analyzed the role of
two probiotic strains of intestinal bacteria, Lactobacillus casei and Bifidobacterium breve in T cell development in the
intestine. B. breve, but not L. casei, induced development of IL-10-producing Tr1 cells that express cMaf, IL-21, and Ahr in the
large intestine. Intestinal CD103
+ dendritic cells (DCs) mediated B. breve-induced development of IL-10-producing T cells.
CD103
+ DCs from Il10
2/2, Tlr2
2/2, and Myd88
2/2 mice showed defective B. breve-induced Tr1 cell development. B. breve-
treated CD103
+ DCs failed to induce IL-10 production from co-cultured Il27ra
2/2 T cells. B. breve treatment of Tlr2
2/2 mice
did not increase IL-10-producing T cells in the colonic lamina propria. Thus, B. breve activates intestinal CD103
+ DCs to
produce IL-10 and IL-27 via the TLR2/MyD88 pathway thereby inducing IL-10-producing Tr1 cells in the large intestine. Oral
B. breve administration ameliorated colitis in immunocompromised mice given naı ¨ve CD4
+ T cells from wild-type mice, but
not Il10
2/2 mice. These findings demonstrate that B. breve prevents intestinal inflammation through the induction of
intestinal IL-10-producing Tr1 cells.
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Introduction
Recent advances in metagenomic analysis of intestinal bacteria
have revealed that inflammatory bowel diseases (IBD) is associated
with dysbiosis in the intestinal microflora [1,2,3]. In support of
these human studies, analysis of mice lacking NLRP6 has revealed
that altered composition of intestinal symbiotic bacteria contrib-
utes to the pathogenesis of colitis [4]. Probiotics, live microorgan-
isms which confer a health benefit on the host when administered
in appropriate amounts, have been used for the treatment of IBD
[5–8]. Probiotics have been shown to modulate the intestinal
symbiotic bacteria leading to the maintenance of intestinal
homeostasis [9,10]. Modulation of microbiota by probiotics has
been shown to be elicited by antagonizing pathogenic bacteria
through the reduction of luminal pH, inhibition of bacterial
adherence, or production of anti-microbial molecules [8].
Probiotics have also been shown to enhance barrier functions of
intestinal epithelial cells [11]. Thus, several mechanisms for the
cross-talk between probiotics and the host have been postulated.
Recent accumulating evidence has indicated that intestinal
commensal microbiota has a great influence on the host intestinal
immune system [12–14]. Commensal microbiota has been shown
to induce IgA-mediated responses and development of Th1/Th17
effector T cells as well as regulatory T (Treg) cells [15–17]. More
recently, a specific microbiota that induces development of Th17
cells or Treg cells has been demonstrated. Segmented filamentous
bacteria (SFB), which have been previously shown to induce IgA-
producing cells in the small intestine, were shown to induce Th17
cell development in the small intestine of mice [18,19]. A human
symbiotic bacterium, Bacteroides fragilis has been shown to mediate
Toll-like receptor 2 (TLR2)-dependent development of Foxp3
+
Treg cells in the large intestine [20–22]. Clostridium species mediate
TLR-independent induction of Foxp3
+ Treg cells in the large
intestine [23]. Thus, several selective intestinal bacteria promote
development of intestinal T cells via distinct mechanisms. Most
recently, microbiota-dependent induction of Foxp3
+ Treg cells has
been shown to be required for the establishment of intestinal CD4
+
T cell homeostasis [24]. Additionally, commensal microbiota has
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+ Treg cells to acquire the antigen-
specific repertoires of their T cell receptors [25]. Probiotics have
also been shown to directly modulate the host immune system,
especially the induction of Foxp3
+ Treg or TGF-b-bearing Treg
cell development [26–29]. Thus, several mechanisms for intestinal
bacteria-dependent development of Foxp3
+ Treg cells have been
postulated.
Intestinal homeostasis is maintained by regulatory T cell
populations consisting of two major CD4
+ T cell subsets; Foxp3
+
Treg cells and IL-10-producing type 1 regulatory T (Tr1) cells
[30]. Tr1 cells modulate immune responses via mechanisms
distinct from those used by Foxp3
+ Treg cells [31]. Indeed, Tr1
cells do not express the master Treg transcription factor Foxp3,
and are induced by distinct cytokines such as IL-10 and IL-27
[32,33]. Tr1 cells are abundant in the intestinal lamina propria
[34], yet it remains unclear how Tr1 cells develop in the intestine.
In this study, we analyzed the effect of two probiotic strains,
Bifidobacterium breve and Lactobacillus casei, on intestinal T cells
responses. Oral administration of B. breve, but not L. casei, resulted
in increased IL-10 production from colonic CD4
+ T cells, without
enhancing Foxp3 expression. B. breve-induced IL-10-producing
CD4
+ T cells possessed properties of Tr1 cells, as evidenced by
expression of cMaf, Il21, and Ahr. B. breve-dependent Tr1 cell
induction was mediated by intestinal CD103
+ dendritic cells via
TLR2/MyD88-dependent production of IL-10 and IL-27. B. breve
administration ameliorated intestinal inflammation in immuno-
compromised mice transferred with naı ¨ve CD4
+ T cells in an IL-
10-dependent manner. These findings establish the mechanisms
for Tr1 cell induction by the probiotic B. breve, which modulates
the host immune responses.
Results
B. breve induces IL-10-producing CD4
+ T cell in the colon
Lactobacillus casei strain Shirota and Bifidobacterium breve Yakult
strain have been proven to be beneficial for the treatment of
several diseases such as diabetes mellitus, arthritis and inflamma-
tory bowel diseases [35–40]. In order to analyze the effect of these
probiotic strains on the intestinal homeostasis, we orally treated
C57BL/6 mice with L. casei and B. breve (10
9 bacteria each) for 3
months. We first analyzed fecal microbiota using both quantitative
PCR and reverse transcription-quantitative PCR methods target-
ing rDNA and rRNA, respectively [41]. Administration of L. casei
and B. breve did not induce a significant change in the number and
composition of microbiota (Text S1, Table S1). Because several
microbiota have been shown to induce differentiation of intestinal
CD4
+ T cells [17], we analyzed production of IL-10, IL-17, and
IFN-cfrom CD4
+ T cells in the small intestine and large intestine
of mice orally treated with L. casei and B. breve. The number of IL-
10-, IL-17-, and IFN-c-producing T cells in both the small
intestine and the large intestine was not altered in mice
administered with L. casei (Figure 1A, B). In B. breve-treated
animals, the number of IL-17- and IFN-c-producing T cells in the
small intestine and the large intestine was not significantly
changed. However, the number of IL-10-producing T cells was
increased about two-fold in the large intestine, but not altered in
the small intestine, spleen, and mesenteric lymph nodes (MLN)
(Figure 1C, D and Figure S1). Thus, administration of B. breve in
C57BL/6 mice selectively increased the number of IL-10-
producing CD4
+ T cells in the large intestine without modulating
intestinal microbiota.
B. breve induces Foxp3
2 IL-10-producing T cells
We next analyzed the effect of B. breve on the BALB/c mouse
strain. BALB/c mice were orally treated with B. breve (10
9 bacteria)
for the indicated time before expression of IL-10 in CD4
+ T cells
of the large intestinal lamina propria was analyzed. The number of
colonic IL-10-producing T cells increased after 2 weeks of
treatment, and by 3 weeks the number of IL-10-producing cells
had doubled (Figure 2A, C). Because IL-10 has been shown to be
produced from Foxp3
+ and Foxp3
2 populations of intestinal T
cells, we analyzed expression of Foxp3 in colonic T cells in B. breve-
treated BALB/c mice. The number of Foxp3
+ CD4
+ T cells in the
large intestine was not altered in B. breve-treated mice (Figure 2B,
D). Therefore, we orally administered B. breve into Foxp3-GFP
mice, and analyzed IL-10 expression in the colonic CD4
+ T cells 3
weeks after beginning treatment. The number of IL-10-producing
cells was increased in the Foxp3
2 population, but not in the
Foxp3
+ population of B. breve-treated mice (Figure 2 E, F). Thus, B.
breve administration selectively increased IL-10-producing Foxp3
2
CD4
+ T cells in the large intestine.
Intestinal CD103
+ DCs promote B. breve-dependent Tr1
cell development
We next analyzed how B. breve induces IL-10-producing T cells.
Because intestinal dendritic cells (DCs) modulate T cell differen-
tiation into effector or regulatory T cells, CD11c
+ cells were
isolated from the colonic lamina propria, stimulated with B. breve
or L. casei, and then co-cultured with splenic naı ¨ve CD4
+ T cells.
After 4 days of the co-culture, T cells were harvested and
stimulated with coated anti-CD3 mAb and soluble anti-CD28
mAb. CD4
+ T cells co-cultured with B. breve-treated, but not L.
casei-treated, intestinal DCs produced high amounts of IL-10
(Figure 3A). We analyzed the effect of other Bifidobacterium spp.
Intestinal DCs treated with B. adolescentis or B. bifidum did not
induce IL-10 production from co-cultured CD4
+ T cells, although
B. longum-treated DCs moderately induced IL-10-producing T cells
(Figure 3B). Thus, B. breve strongly induced IL-10-producing T
cells via activation of intestinal DCs. In contrast to high induction
of IL-10, B. breve-treated intestinal CD11c
+ cells did not induce
Foxp3 expression in co-cultured CD4
+ T cells (Figure 3C). IL-10-
producing Foxp3
2 T cells have been characterized as type 1
regulatory T (Tr1) cells expressing c-Maf, aryl hydrocarbon
receptor (Ahr) and IL-21 [42–44]. Therefore, we analyzed
expression of cMaf, Ahr and Il21. Expression of cMaf, Ahr and
Il21 was increased in CD4
+ T cells co-cultured with B. breve-
treated, but not L. casei-treated, intestinal CD11c
+ cells (Figure 3D).
These findings indicate that B. breve-treated intestinal DCs
promote the induction of IL-10-producing Tr1 cells.
Author Summary
Unlike induction of Foxp3
+ regulatory T cell development,
it remains unclear how intestinal environmental factors
regulate development of another regulatory T cell subset,
Tr1 cells that produce IL-10. In this study, we reveal that a
probiotic strain, Bifidobacterium breve induces IL-10-
producing Tr1 cells that express c-Maf, IL-21, and Ahr via
activation of intestinal CD103
+ DCs in the large intestine.
Using several gene-targeted mice, we show that B. breve-
induced development of IL-10-producing Tr1 cells is
dependent on DC secretion of IL-10 and 27 via a TLR2/
MyD88 pathway. We finally show that B. breve ameliorated
T cell-dependent colitis in immunocompromised mice via
T cell production of IL-10. These findings demonstrate that
B. breve maintains intestinal homeostasis through the
induction of intestinal IL-10-producing Tr1 cells.
B. breve Induces Colonic IL-10-Producing Tr1 Cells
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+
CX3CR1
2 CD11b
2 DCs (CD103
+ DCs) and CX3CR1
+
CD11b
+ DCs (CX3CR1
+ DCs) [45,46]. Therefore, we analyzed
which subset mediates B. breve-dependent Tr1 cell development.
CD103
+ DCs and CX3CR1
+ DCs were isolated from the colonic
lamina propria, treated with B. breve, and then co-cultured with
naı ¨ve CD4
+ T cells. CD4
+ T cells co-cultured with B. breve-treated
CD103
+ DCs, but not CX3CR1
+ DCs, produced high amounts of
IL-10 (Figure 4A, B). B. breve caused a dose-dependent increase in
IL-10 production from T cells co-cultured with CD103
+ DCs
(Figure S2). CD103
+ DCs have been shown to induce Foxp3
+
Treg cells [47,48]. Indeed, CD103
+ DCs induced low levels of
Foxp3 expression on co-cultured CD4
+ T cells even in the absence
of TGF-b or retinoic acid (Figure 4B). However, B. breve-treated
CD103
+ DCs did not induce Foxp3 expression, but induced
enhanced IL-10 production in co-cultured T cells.
Next, we analyzed whether intestinal CD103
+ DCs in B. breve-
treated mice instruct Tr1 cell development. Since CD103
+ DCs
have been postulated to sample intestinal antigens in the lamina
propria and move to MLN where they induce Foxp3
+ T cells [49],
we analyzed CD103
+ DCs in MLN and colonic lamina propria.
C57BL/6 mice were fed with B. breve for 3 weeks, before CD103
+
Figure1. Induction of IL-10-producing CD4
+ T cells by B. breve in the colonic lamina propria. 6-week-old C57BL/6 mice were fed L. casei or B.
breve or placebo daily(each,1610
9) byoral gavagefor3 months(n=8). Intestinal laminapropria lymphocytes were analyzedforcytokineproductionby
flowcytometry.PercentagesofIL-10-,IL-17-,andIFN-c-producingCD4
+TcellsofmiceadministeredwithL.casei(A)o rB.breve(C)wereshown.*P,0.05.
(B, D) Representative FACS dot plots showing production of IL-10 and IFN-c gated on colonic CD4
+ T cells in the indicated mice.
doi:10.1371/journal.ppat.1002714.g001
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2 IL-10-producing CD4
+ T cells by B. breve. 6-week-old BALB/c mice were administered with B. breve or placebo
orally for 1–4 weeks (n=5). At the indicated time point, mice were sacrificed and CD4
+ T cells in the colonic lamina propria were analyzed by flow
cytometry. Percentages of CD4
+ IL-10
+ T cells (A), and CD4
+ Foxp3
+ T cells (B) are shown. *P,0.02. Representative FACS dot plots for IL-10
+ and IL-17
+
T cells (C), and histogram for Foxp3
+ T cells (D) gated on CD4
+ T cells are shown. (E) Foxp3
GFP mice were fed with B. breve for 4 weeks. CD4
+ T cells in
the colonic lamina propria were analyzed for expression of GFP and IL-10. (F) Percentages of IL-10
+ T cells in Foxp3
+ or Foxp3
2 CD4
+ T cells (n=5).
Data are representative of two independent experiments; means 6 S.D. *P,0.02.
doi:10.1371/journal.ppat.1002714.g002
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PLoS Pathogens | www.plospathogens.org 4 May 2012 | Volume 8 | Issue 5 | e1002714Figure 3. Intestinal DCs mediate B. breve-dependent Tr1 cell development. CD11c
+ DCs (5610
4) were isolated from the colonic lamina
propria, and cultured with B. breve, L. casei, B. adolescentis, B. longum,o rB. bifidum (5610
4) for 24 h. After washing, DCs were co-cultured with splenic
naı ¨ve CD4
+ T cells (5610
4) in the presence of soluble anti-CD3 mAb for 4 days. (A) T cells were harvested and re-stimulated with plate-bound anti-
CD3 and soluble anti-CD28 mAbs for 24 h. IL-10 concentrations in the culture supernatants were analyzed by ELISA. *P,0.001. (B) T cells were
harvested and re-stimulated with plate-bound anti-CD3 and soluble anti-CD28 mAbs for 24 h. IL-10 concentrations in the culture supernatants were
analyzed by ELISA. *P,0.001. (C) T cells were collected, and then stained for CD4 and Foxp3. Foxp3 expression in CD4
+ cells is shown. (D) T cells were
harvested, and stimulated with anti-CD3 and anti-CD28 mAbs for 4 h. Total RNA was then extracted to analyze expression of cMaf, Il21, and Ahr by
quantitative real-time RT-PCR. Data are representative of five independent experiments and show mean values 6 S.D. of triplicate determinations.
*P,0.05, **P,0.01.
doi:10.1371/journal.ppat.1002714.g003
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cultured with naive CD4
+ T cells. CD4
+ T cells co-cultured with
CD103
+ DCs from the colonic lamina propria of B. breve-fed mice
showed higher IL-10 production, with lower levels observed in
CD4
+ T cells co-cultured with MLN CD103
+ DCs (Figure 4C).
Thus, intestinal CD103
+ DCs possess an enhanced capacity to
Figure 4. CD103
+ DCs, but not CX3CR1
+ DCs, induce B. breve-dependent Tr1 cell differentiation. CD103
+ CX3CR1
2 CD11b
2 CD11c
+ DCs
(CD103
+ DCs) and CX3CR1
+ CD11b
+ CD11c
+ DCs (CX3CR1
+ DCs) were isolated from the colonic lamina propria, and treated with the same numbers of
B. breve for 24 h. After washing, splenic naı ¨ve CD4
+ T cells were co-cultured with B. breve-treated CD103
+ DCs or CX3CR1
+ DCs in the presence of anti-
CD3 mAb for 4 days. (A) T cells were then harvested and re-stimulated for 24 h to analyze IL-10 production by ELISA. *P,0.05. (B) T cells were
collected, and re-stimulated with PMA and ionophore for 8 h. Intracellular expression of Foxp3 and IL-10 was then analyzed by flow cytometry. (C)
C57BL/6J mice (n=5) were fed with B. breve for 3 weeks. Then, CD103
+ DCs were isolated from MLN and the colonic lamina propria, and co-cultured
with splenic naı ¨ve CD4
+ T cells. The co-cultured T cells were re-stimulated and IL-10 concentration in the supernatants was analyzed by ELISA. Data
are representative of four independent experiments and show mean values 6 S.D. of triplicate determinations. *P,0.05, **P,0.01.
doi:10.1371/journal.ppat.1002714.g004
B. breve Induces Colonic IL-10-Producing Tr1 Cells
PLoS Pathogens | www.plospathogens.org 6 May 2012 | Volume 8 | Issue 5 | e1002714induce Tr1 cells by B. breve treatment in mice. These findings
indicate that intestinal CD103
+ DCs are responsible for B. breve-
dependent Tr1 cell development.
B. breve induces Tr1 cells via IL-10 and IL-27
IL-10 was originally shown to induce Tr1 cells [50].
Subsequently, IL-27 was identified as a growth and differentiation
factor for Tr1 cells [51–53]. Therefore, we analyzed expression of
these key cytokines in B. breve-treated CD103
+ DCs. B. breve
treatment increased expression of Il27p28, Ebi3 (both of which
encode subunits of IL-27), and Il10 in CD103
+ DCs (Figure 5A).
Furthermore, neutralizing mAb to IL-10 or IL-27 severely or
moderately blocked B. breve-mediated development of Tr1 cells,
respectively, and combination of both mAbs almost completely
blocked Tr1 cell development. In contrast, neither a retinoic acid
receptor antagonist LE540 nor anti-TGF-b neutralizing Ab
inhibited B. breve-mediated Tr1 cell induction (Figure 5B and
Figure S3). These findings indicate that IL-10 and IL-27, which
are produced from B. breve-treated CD103
+ DCs, mediate Tr1 cell
development. In order to corroborate these findings, we analyzed
Il10
2/2 and Il27ra
2/2 mice. We first treated CD103
+ DCs from
the colonic lamina propria of wild-type or Il10
2/2 mice with B.
breve, before co-culturing them with wild-type naı ¨ve CD4
+ T cells.
CD4
+ T cells co-cultured with B. breve-treated Il10
2/2 DCs
produced severely decreased levels of IL-10 (Figure 5C). Then,
CD4
+ T cells were isolated from the spleen of Il27ra
2/2 mice and
co-cultured with B. breve-treated wild-type CD103
+ DCs. IL-10
production from Il27ra
2/2 T cells was severely decreased
(Figure 5D). Taken together, these findings demonstrate that IL-
10 and IL-27, which are produced by B. breve-treated CD103
+
DCs, cooperatively mediateTr1 cell induction.
B. breve induces Tr1 cells in a TLR2/MyD88-dependent
manner
We next analyzed which signaling pathway is responsible for B.
breve-dependent production of IL-10 and IL-27 from CD103
+
Figure 5. IL-10/IL-27-dependent Tr1 cell development by B. breve-treated DCs. (A) CD103
+ DCs were isolated from the colonic lamina
propria, and incubated with B. breve for 4 h. Total RNA was extracted and analyzed for mRNA expression of Il27p28, Ebi3, and Il10 by quantitative real-
time RT-PCR. N.D, not detected. **P,0.01, ***P,0.001. (B) Naı ¨ve T cells were co-cultured with B. breve-treated CD103
+ DC in the presence of the
indicated neutralizing antibody for 4 days. T cells were then harvested and re-stimulated with anti-CD3 and CD28 mAbs for 24 h. IL-10 concentrations
in the supernatants were measured by ELISA. *P,0.05, **P,0.01, ***P,0.001, N.S, not significant. (C) CD103
+ DCs were isolated from the colonic
lamina propria of wild-type and Il10
2/2 mice (C57BL/6 background) and incubated with B. breve. Naı ¨ve CD4
+ T cells from wild-type C57BL/6 mice
were then co-cultured with B. breve-treated DCs. T cell production of IL-10 was analyzed by ELISA. N.D, not detected. (D) CD103
+ DCs were isolated
from the colonic lamina propria of wild-type BALB/c mice and incubated with B. breve. Naı ¨ve CD4
+ T cells from wild-type and Il27ra
2/2 mice (BALB/c
background) were then co-cultured with B. breve-treated DCs. T cell production of IL-10 was measured by ELISA. Data are representative of three
independent experiments and show mean values 6 S.D. of triplicate determinations. *P,0.05.
doi:10.1371/journal.ppat.1002714.g005
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innate immunity through the recognition of microbe-associated
molecular patterns [54]. Therefore, we analyzed the involvement
of Toll-like receptor (TLR) signaling using Myd88
2/2 mice. In
intestinal CD103
+ DCs from Myd88
2/2 mice, B. breve-induced
expression of Il27p28, Ebi3, and Il10 was severely reduced
(Figure 6A). Furthermore, wild-type CD4
+ T cells, which were
co-cultured with B. breve-treated Myd88
2/2 CD103
+ DCs, failed to
produce IL-10 (Figure 6B). These findings indicate that the TLR
signaling pathway in CD103
+ DCs is critically involved in B. breve-
mediated Tr1 cell development. We further analyzed which TLR
mediates B. breve-mediated responses. B. breve-induced expression
of Il27p28, Ebi3, and Il10 was severely reduced in intestinal
CD103
+ DCs of Tlr2
2/2 mice (Figure 6C). In addition, B. breve-
treated Tlr2
2/2 CD103
+ DCs did not promote the development
of IL-10-producing T cells (Figure 6D). B. breve-treated Tlr4
2/2
and Tlr9
2/2 CD103
+ DCs induced IL-10-producing cells
normally (Figure S4). CD103
+ DCs treated with the TLR2 ligand,
but not TLR4 or TLR5 ligand, induced Tr1 cells, albeit reduced
when compared with B. breve (Figure S5). The critical involvement
of the TLR2-mediated pathway in B. breve-dependent Tr1
induction was further confirmed in Tlr2
2/2 mice orally admin-
istered with B. breve for 4 weeks (Figure 6E, F). In Tlr2
2/2 mice, B.
breve treatment did not increase the number of IL-10-producing
CD4
+ T cells in the colonic lamina propria. Taken together, these
findings demonstrate that the TLR2/MyD88-dependent pathway
in CD103
+ DCs mediates B. breve-mediated Tr1 cell induction.
B. breve improves intestinal inflammation via induction of
T cell IL-10 production
Probiotic strains of bacteria have been shown to be used for the
treatment of several diseases including IBD [5–8]. Therefore, we
analyzed the effect of oral B. breve treatment in intestinal
inflammation caused by transfer of naı ¨ve CD4
+ T cells into
immune-compromised severe combined immunodeficiency
(SCID) mice. Daily treatment with B. breve markedly improved
the severity of intestinal inflammation (Figure 7 A, D, E). In B.
breve-treated SCID mice, IL-10 concentration in the colonic tissues
was increased, whereas IFN-c concentration was decreased
(Figure 7C). We then analyzed whether IL-10 was responsible
for the prevention of intestinal inflammation. SCID mice were
transferred with naı ¨ve CD4
+ T cells from Il10
2/2 mice and orally
treated with B. breve. No effect on the amelioration of intestinal
inflammation in SCID mice given Il10
2/2 CD4
+ T cells was
observed (Figure 7B, D, E). These findings demonstrate that T
cell-derived IL-10 suppresses T cell-dependent intestinal inflam-
mation in B. breve-treated SCID mice.
Discussion
In the present study, we show that probiotic B. breve promotes
development of IL-10-producing Tr1 cells in the colon without
altering the composition of intestinal commensal flora. Intestinal
CD103
+ DCs mediate B. breve-induced development of Tr1 cells
via the TLR2/MyD88-dependent induction of IL-27 and IL-10.
Recent accumulating evidence has indicated that specific micro-
biota influence the development of intestinal T cells. Segmented
filamentous bacteria have been shown to induce Th17 cells in the
small intestine [18,19]. Polysaccharide A (PSA) of B. fragilis has
been shown to promote Foxp3
+ Treg cell development via TLR2
expressed on T cells in the large intestine [21], while Clostridium
species have been shown to induce Foxp3
+ Treg cells in the colon
through TGF-b induction of epithelial cells [23]. Several probiotic
strains of commensal bacteria have also been shown to induce
Foxp3
+ Treg cells or TGF-b expressing Treg cells [27–29,55].
Several studies have also indicated that selective probiotics induce
IL-10 production in the intestine or the development of IL-10-
producing T cells in vitro [26,29,56]. However, the precise
mechanism by which probiotics induce IL-10-producing T cells
in the intestinal lamina propria remained unknown. This study
clearly demonstrates that a probiotic strain of bacteria, B. breve,
promotes development of Foxp3
2 Tr1-type of T cells.
Several recent studies have demonstrated that colonization of
specific microbiota in germ-free mice induced development of
Treg cells and Th17 cells [18,19,21,23]. However, oral adminis-
tration of probiotic B. breve did not induce colonic Tr1 cells in
germ-free mice. This might be due to that fact that B. breve has a
low ability to colonize in the intestine by itself. As was the case in
other studies [18,19,21,23], germ-free mice received single
administration of B. breve. However, due to the low ability to
colonize in the intestine, B. breve might not be able to induce Tr1
cell development by single administration. Alternatively, this
probiotic strain might require assistance by other commensal
bacteria to be uptaken or recognized by intestinal DCs. A low
ability for colonization in the intestine of B. breve might correlate
with the fact that oral administration of this bacterium did not
induce apparent change in the composition of commensal
microbiota.
Tr1 cells were identified as the second subset of CD4
+
regulatory T cells [50]. Both Foxp3
+ Treg cells and Tr1 cells
are critically involved in the maintenance of intestinal homeostasis
[30]. In vitro studies demonstrated that IL-10 and IL-27 are critical
for the induction of Tr1 cells [51–53]. The present study shows
that intestinal Tr1 cells are induced by both IL-10 and IL-27,
which is produced by intestinal CD103
+ DCs that are exposed to
B. breve. However, Tr1 cells are present in the intestinal lamina
propria of mice that are not fed with B. breve [34]. In this regard,
given that there are many types of Bifidobacterium species in the
intestine (Table S1), these indigenous Bifidobacterium might
contribute to development of intestinal Tr1 cells. Indeed, our
data suggest that B. longum, one of indigenous commensal bacteria,
moderately induced Tr1 cells. The B. breve-induced increase in Tr1
cells was observed in the large intestine, but not in the small
intestine. This might be due to the characteristics of B. breve, which
preferentially colonize in the large intestine rather than the small
intestine [57].
B. breve-induced Tr1 cell development depends on the TLR2/
MyD88 pathway. The TLR pathways play mandatory roles in the
elimination of pathogenic microorganisms [54]. Previous studies
indicated that mice deficient in MyD88, TLR2, or TLR4 were
highly sensitive to intestinal inflammation induced by dextran
sodium sulfate treatment [58,59]. However, the mechanism for the
TLR-dependent maintenance of gut homeostasis remains unclear.
This study demonstrates that the TLR2 pathway in DCs is
beneficial for the suppression of intestinal inflammation via
induction of IL-10-producing Tr1 cells. It is interesting to note
that Tr1 cells are present in Tlr2
2/2 and Myd88
2/2 mice,
indicating that Tr1 cell development in the intestine in steady
states is induced independently of TLR signaling. The TLR-
independent induction of intestinal Tr1 cells might be induced by
other, so-far unknown, bacteria.
Our in vitro experiments clearly indicate that intestinal CD103
+
CX3CR1
2 CD11b
2 DCs respond to B. breve and promote Tr1 cell
development. Intestinal CD103
+ DCs residing in the colonic
lamina propria and MLN showed enhanced capacity to induce IL-
10-producing Tr1 cells after B. breve treatment. CD103
+ DCs from
MLN were less effective in Tr1 cell induction compared to the
lamina proprial CD103
+ DCs. Thus, it is possible that CD103
+
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PLoS Pathogens | www.plospathogens.org 8 May 2012 | Volume 8 | Issue 5 | e1002714Figure 6. B. breve induces Tr1 cells in a TLR2/MyD88-dependent manner. (A, C) CD103
+ DCs were isolated from the colonic lamina propria
of wild-type, Myd88
2/2 (A) and Tlr2
2/2 (C) mice, incubated with B. breve for 4 h, and then analyzed for mRNA expression of Il27p28, Ebi3, and Il10.
*P,0.05, **P,0.01. (B, D) Wild-type, Myd88
2/2 (B) and Tlr2
2/2 (D) CD103
+ DCs were incubated with B. breve for 24 h, and then co-cultured with
naı ¨ve CD4
+ T cells from wild-type mice for 4 days. T cells were harvested and re-stimulated for 24 h. IL-10 production in the supernatants was
analyzed by ELISA. Data are representative of three independent experiments and show mean values 6 S.D. of triplicate determinations. *P,0.05.
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characteristics in Tr1 cell induction. In addition, it remains
unclear how CD103
+ DCs sense B. breve in the intestinal mucosa.
CX3CR1-expressing intestinal DCs have been shown to extend
their dendrites into the intestinal lumen to sample luminal contents
[60]. However, CD103
+ DCs do not express the CX3CR1 that is
required for dendrite extension. Several metabolites produced by
commensal microbiota have been shown to influence host cell
gene expression [61]. However, culture supernatants of B. breve did
not induce IL-10 production from T cells co-cultured with
CD103
+ DCs, indicating that B. breve directly acts on intestinal
DCs (Figure S6). Elucidating how CD103
+ DCs recognize B. breve
in the intestinal lamina propria would be a future interesting issue.
IL-10-producing Tr1 cells can be induced by UV-irradiated B.
breve, or even sonicated B. breve (Figure S7). These findings indicate
that components of B. breve directly act on intestinal DCs, possibly
by interacting with TLR2, and promote Tr1 cell development.
TLR2 has been shown to recognize a unique polysaccharide
structure (PSA) of B. fragilis to induce Foxp3
+ Treg cells [21]. The
probiotic strain of B. breve used in this study also possesses a unique
structure of polysaccharide in their cell walls [62]. Therefore, it
would be interesting in the future to analyze whether the
polysaccharide of B. breve is recognized by TLR2 to induce Tr1
cells. Identification of such B. breve components that activate the
TLR2 pathway will lead to development of a new effective agent
for the treatment of IBD.
In contrast to the development of Tr1 cells promoted by B. breve,
L. casei did not have any effect on the differentiation of intestinal T
cells, although it is well known as a beneficial probiotic strain
possessing several health-promoting effects [63]. In this regard,
several mechanisms of action of probiotics, other than the
influence on the host T cell development, have been postulated
[7,8]. These include enhancement of barrier functions of epithelial
cells, modification of commensal flora, and effects on dendritic
cells and monocytes/macrophages. Several mechanisms of
Lactobaciluus species-mediated actions have been reported
[55,56,64]. Our results indicate that each probiotic strain has
their specific modes of action on the host. VSL#3 containing
several probiotics (three bifidobacteria, five lactobacilli and
Streptococcus salivarius subsp. thermophilus) have been reported to
have potent effects on host health and diseases [26]. This might be
due to the synergistic effect of these different probiotic strains that
have distinct mechanisms of actions.
In the present study, we show that a probiotic bacterium, B.
breve, induces intestinal Tr1 cells and thereby improves intestinal
inflammation. Analysis of the effect of this probiotic-dependent
Tr1 cell development on other disease models will expand the
application of B. breve as a therapeutic agent.
Materials and Methods
Ethics statement
All animal experiments were carried out in strict accordance
with the Guidelines for Animal Experimentation of the Japanese
Association for Laboratory Animal Science. The protocol was
approved by the committee for Animal Experiments of Osaka
University (Permit Number: 21-058-0).
Reagents
Lactobacilus casei strain Shirota (L. casei)a n dBifidobacterium breve
Yakult strain (B. breve) were as described [35,40]. B. bifidum (Yakult
strain YIT10347), B. adolescntis (ATCC15703), and B. longum
(ATCC15707) were used for experiments. For oral treatment of
mice, freeze-dried preparations of L. casei and B. breve were dissolved
with distilled water, and 1610
9 bacteria were administered. A
sachet of B. breve contained 4610
9 freeze-dried living bacteria,
cornstarch, and hydroxypropyl cellulose as vehicle. Placebo sachet
of B. breve contained only cornstarch and hydroxypropyl cellulose. A
sachet of L. casei consisted of 5610
9 freeze-dried living bacteria with
lactose, cornstarch, powdered skim milk, crystallized cellulose and
hydroxypropyl cellulose. The placebo sachet of L. casei consisted of
only common excipients. For in vitro stimulation, B. breve was
inoculated in GAM broth (Nissui Pharmaceutical) supplemented
with 1%(w/v) glucose, and cultured for 24 h at 37uC under
anaerobic conditions, and then centrifuged and the pellets were
suspendedwithculturemedia.ThenumberofB.brevewasmeasured
by culturingon MRSagar plate. Neutralizing anti-mouse IL-10 was
purchased from BD biosciences, anti-mouse IL-27p28, and anti-
TGF-b (1D11) blocking antibodies were purchased from R&D
systems. Anti-mouse CD3 (145-2C11) and CD28 (37.51) were
obtained from BioLegend. LE540 was purchased from WAKO
Chemicals (Tokyo, Japan).
Animals
BALB/c and C57BL/6J mice were purchased from CLEA
Japan or Japan SLC. CB17-SCID mice were obtained from
CLEA Japan. Il10
2/2, Foxp3
eGFP were purchased from Jackson
laboratories, and Myd88
2/2, Tlr2
2/2, Tlr4
2/2 and Tlr9
2/2 mice
were generated previously [65]. Il27ra
2/2 mice were kindly
provided by Amgen [66]. These mice were backcrossed eight or
more generations onto BALB/c or C57BL/6J. C57BL/6J mice
were orally administered with L. casei or B. breve (10
9 bacteria each)
as well as placebo daily with gastric tubes for 3 months.
Alternatively, probiotics were orally introduced into BALB/c,
C57BL/6J, or Foxp3
eGFP mice for 1–4 weeks.
Analysis of fecal microbiota
Methodsforthe analysisoffecal bacteriaaredescribedinTextS1.
Flow cytometry
For flow cytometry, the following antibodies were used: PerCP/
Cy5.5-conjugated anti-CD4 (GK1.5), Alexa Fluor 647-conjugated
CD11c (N418), CD62L (MEL-14), streptavidin-conjugated PE/
Cy7 from BioLegend, FITC-conjugated anti-CD11b (M1/70),
CD25 (7D4), and PE-conjugated CD103, anti-mouse CD16/32
(Fcc III/II receptor) from BD PharMingen, PE-conjugated CD44
(IM7), Alexa Fluor 647-conjugated Foxp3 (FJK-16s), and biotin-
conjugated CX3CR1 from eBiosciences. Flow cytometric analysis
was performed using a FACS Canto II flow cytometer (BD
Biosciences) with FlowJo software (Tree Star).
Isolation of intestinal lamina propria DC subsets and
lymphocytes
Lamina propria DCs and lymphocytes were isolated as
previously described [67] with simple modifications. Briefly,
N.D, not detected. (E) 6-week-old wild-type and Tlr2
2/2 mice (BALB/c background) were fed with B. breve or placebo for 3 weeks (n=5). Then, the
mice were sacrificed and colonic lamina propria lymphocytes were analyzed for IL-10 production by flow cytometry. The percentage of IL-10
+ cells
gated on CD4
+ T cells is shown in the indicated mice. Data are representative of three independent experiments and show mean values 6 S.D. of
triplicate determinations. *P,0.05. (F) Representative FACS plots of IL-10- and IFN-c-producing CD4
+ T cells were shown.
doi:10.1371/journal.ppat.1002714.g006
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PLoS Pathogens | www.plospathogens.org 10 May 2012 | Volume 8 | Issue 5 | e1002714Figure 7. IL-10-dependent amelioration of intestinal inflammation by B. breve. (A, C) 6 week-old SCID mice (n=8 per group) were
intraperitoneally injected with PBS or 3610
5 of naı ¨ve CD4
+ T cells from wild-type BALB/c mice (A) or Il10
2/2 mice (BALB/c background) (B). The mice
were orally administered daily with B. breve from 1 week before the T cell transfer to the end of experiment. Changes in body weight were monitored
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PLoS Pathogens | www.plospathogens.org 11 May 2012 | Volume 8 | Issue 5 | e1002714colons and small intestines were opened longitudinally and
vigorously rinsed in PBS. Intestines were shaken in HBSS
containing 5 mM EDTA and 5% fetal bovine serum (FBS) for
20 min at 37uC. After removal of epithelial layers and fat tissues,
the intestines were cut into small pieces and incubated with RPMI
1640 containing 5% FBS, 1 mg/ml of collagenase D (Roche
Diagnostics), 1 mg/ml of dispase (Invitrogen) and 40 mg/ml of
DNase I (Roche Diagnostics) for 1 h at 37uC in a shaking water
bath. The digested tissues were washed with HBSS containing
5 mM EDTA. Cell suspensions were filtered through a 40 mm cell
strainer into chilled PBS and centrifuged. Cell suspensions from
enzyme digestion were then applied to a Percoll (GE Healthcare)
gradient (for DCs: 30% percoll on top, 75% percoll on the bottom,
and for lymphocytes: 40% percoll on top, 80% percoll on the
bottom) by centrifugation at 780 g for 20 min at 25uC. The cells at
interface were taken and washed twice with FACS buffer. For
purifying lamina propria DC subsets, single cell suspensions were
treated with anti-mouse Fcc receptor antibody for 5 min at 4uC.
Cells were then stained with CD11c-APC, CD11b-FITC, CD103-
PE and CX3CR1-PE-Cy7 and subsequently sorted using a
FACSAria (BD Biosciences) to a purity .98%. The cells were
used immediately for each of experiment.
Isolation of splenic naı ¨ve CD4
+ cells
To prepare single-cell suspensions from spleens, they were
ground between glass slides and passed through a 40 mm cell
strainer. Splenocytes were treated with RBC lysis buffer (0.15 M
NH4Cl, 1 mM KHCO3, 0.1 mM EDTA) for 5 min and washed
twice with PBS. For FACS sorting, cells were stained with PerCP/
Cy5.5-conjugated anti-CD4 (Biolegend), APC-conjugated anti-
CD62L, FITC-conjugated anti-CD25 and PE-conjugated anti-
CD44 (BD Biosciences). Naı ¨ve CD4
+ T cells were sorted using a
FACSAria for CD4
+CD62L
highCD25
2CD44
low. The purity of the
sorted cells was routinely .98%.
Intracellular cytokine staining
The intracellular expression of IFN-c, IL-17, and IL-10 in
CD4
+ T cells was analyzed using the Cytofix/Cytoperm Kit Plus
(with Golgistop; BD Biosciences) according to the manufacturer’s
instructions. In brief, lymphocytes obtained from the intestinal
lamina propria were incubated with 50 ng/ml of phorbol
myristate acetate (PMA; Sigma) and 5 mM of calcium ionophore
A23187 (Sigma) and Golgistop in complete RPMI1640 at 37uC
for 4 h. Surface staining was performed with PerCP/Cy5.5-
conjufated anti-CD4 for 20 min at 4uC. After Fix/Perm treatment
for 20 min, intracellular cytokine staining was performed with PE-
conjugated anti-IL-10, FITC-conjugated anti-IFN-c, and APC-
conjugated anti-IL-17 for 20 min. Data were acquired using a
FACS Canto II and analyzed using FlowJo software. Alternatively,
for intracellular staining for Foxp3 and IL-10, cells were stained
using the Foxp3 Staining Buffer set (eBiosciences).
In vitro co-culture assays
Colonic DC subsets (5610
4) were incubated with the same
number or the indicated number of L. casei or B. breve in 100 mlo f
complete RPMI1640 media for 24 h in a round-bottom 96 well
plate. DCs were then washed with PBS and naı ¨ve CD4
+ T cells
(5610
4) were added into the culture with 2 mg/ml soluble anti-
CD3 mAb. After 4 days, T cells were collected, washed and
counted. The same numbers of T cells were re-stimulated with
plate-bound anti-CD3 mAb (2 mg/ml) and soluble anti-CD28
mAb (2 mg/ml) for 24 h. Re-stimulated T cell cytokine production
in the supernatants was analyzed by ELISA (R&D systems).
Alternatively, T cells were re-stimulated with 50 ng/ml of PMA
and 5 mM of calcium ionophore A23187 for 6 h before
intracellular cytokine staining was performed as described above.
Golgistop was added for the last 2 h.
Quantitative real-time RT–PCR
Total RNA was isolated with the RNeasy Mini Kit (Qiagen),
and 1–2 mg of total RNA was reverse transcribed using M-MLV
reverse transcriptase (Promega) and random primers (Toyobo)
after treatment with RQ1 DNase I (Promega). Complementary
DNAs were analyzed by qPCR using the GoTaq qPCR Master
Mix (Promega) on an ABI 7300 system (Applied Biosystems). All
values were normalized to the expression of Gapdh encoding
glyceraldhyde-3-phosphate dehydrogenase, and the fold difference
in expression relative to that for Gapdh is shown. Amplification
conditions were: 50uC (2 min), 95uC (10 min), and 40 cycles of
95uC (15 s) and 60uC (60 s). The following primer sets were used:
cMaf,5 9-AATCCTGGCCTGTTTCACAT-39 and 59-TGACGC-
CAACATAGGAGGTG-39; Il21,5 9-GCCAGATCGCCTCCT-
GATTA-39 and 59-CATGCTCACAGTGCCCCTTT-39; Il27p28,
59-TTCCCAATGTTTCCCTGACTTT-39 and 59-AAGTGTG-
GTAGCGAGGAAGCA-39; Ebi3,5 9-TGAAACAGCTCTCGT-
GGCTCTA-39 and 59-GCCACGGGATACCGAGAA-39; Il10,
59-TTTCAAACAAAGGACCAG-39 and 59-GGATCATTTCC-
GATAAGG-39; and Gapdh,5 9-TGTGTCCGTCGTGGATC-
TGA-39 and 59-CCTGCTTCACCACCTTCTTGA-39
T-cell-mediated colitis model
Naive CD4
+CD62L
highCD25
2CD44
low splenic T cells from
BALB/c mice or Il10
2/2 mice (BALB/c background) were
purified and intraperitoneally transferred into SCID mice (3610
5
cells per mouse). B. breve (10
9 bacteria) were fed by oral gavage
from 3 days before the transfer to the end of the experiments.
Weight changes were monitored every day. The mice were
sacrificed, and the colons were examined histochemically after
haematoxylin and eosin staining. Alternatively, the colons were cut
into small pieces after wash and cultured for 24 h. Then, culture
supernatants were collected and the level of IL-10, IL-17A and
IFN-c was measured by ELISA (R&D systems).
Histopathological analysis
Paraffin-embedded colon samples were sectioned and stained
with hematoxylin and eosin. Severity of colitis was evaluated by
the standard scoring system as previously described [68]. Five
regions of the colon (cecum; ascending, transverse, and descending
of colon; and rectum) were graded semiquantitatively from 0 (no
change) to 5 (most severe change). The grading represents an
increasing incidence and degree of inflammation, goblet cell loss,
ulceration and fibrosis in the lamina propria. The scoring was
performed in a blinded manner. Images of hematoxylin and eosin
staining and May-Grunwald-Giemsa staining were taken using
Biozero (Keyence).
daily and presented relative to initial body weight. *P,0.05, Error bars, S.E.M. (C) Production of IL-10, IL-17 and IFN-c from the colon of wild-type T
cell-transferred SCID mice daily administered with B. breve or placebo (n=5 per group). *P,0.0064, **P,0.0005. (D) Hematoxylin and eosin staining
of colon sections at 4 weeks after the transfer. Original magnification,6400. (E) Clinical scores for colitis were shown in the indicated group. Data are
representative of two independent experiments. *P,0.05, **P,0.01. N.S, not significant.
doi:10.1371/journal.ppat.1002714.g007
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Statistical analysis was performed using PRISM 4 software.
Unpaired student’s t-test and Mann-Whitney U test were used to
determine the significance of experiments. P values of less than
0.05 were considered statistically significant.
Supporting Information
Figure S1 Percentage of IL-10
+ or Foxp3
+ CD4
+ T cells in
MLN or spleens were not changed by oral treatment of
B. breve. 6-week-old C57BL/6 mice were fed with B. breve or
placebo daily by oral gavage for 3 months (n=8). MLNs and
spleens were taken, and analyzed for expression of cytokines and
Foxp3 by flow cytometry. Representative FACS dot plots were
shown gated on CD4
+ T cells. A: MLN, B: Spleen.
(PDF)
Figure S2 B. breve induces IL-10-producing Tr1 cells in
a dose-dependent manner. CD11c
high CD11b
2CD103
+ DCs
(CD103
+ DCs) (5610
4) were isolated from the colonic lamina
propria of C57BL/6J mice, and treated with the increasing
numbers of B. breve (5610
1 to 5610
5) for 24 h in round-bottom 96-
well plate. After washing, splenic naı ¨ve CD4
+ T cells (5610
4) were
co-cultured with B.breve-treated CD103
+ DC in the presence of
anti-CD3 mAb for 4 days. Then, T cells were harvested and re-
stimulated. IL-10 production in the culture supernatants was
analyzed by ELISA. Data are representative of two independent
experiments. Error bars, S.D. *P,0.05, **P,0.01.
(PDF)
Figure S3 Retinoic acid-independent induction of Tr1
cells by B. breve. B. breve-treated CD103
+ DCs were co-cultured
with splenic naı ¨ve CD4
+ T cells in the presence of an inhibitor of
retinoic acid receptor (2 mM of LE540, WAKO chemicals,
JAPAN) for 4 days. IL-10 production by re-stimulated T cells
was quantified by ELISA. Data are representative of two
independent experiments. Error bars, S.D. *P,0.01, N.S, not
significant.
(PDF)
Figure S4 TLR4/TLR9-independent induction of Tr1
cells by B. breve. Intestinal CD103
+ DCs from wild-type,
Tlr4
2/2 and Tlr9
2/2 mice were treated with B. breve for 24 h, and
then co-cultured with splenic naı ¨ve CD4
+ T cells for 4 days. IL-10
production by re-stimulated T cells was quantified by ELISA.
Data are representative of two independent experiments. Error
bars, S.D. *P,0.01.
(PDF)
Figure S5 TLR2-dependent induction of Tr1 cells.
Intestinal CD103
+ DCs were stimulated with B. breve or TLR
ligands such as LPS (TLR4 ligand), Pam3 (TLR2 ligand) or
flagellin (TLR5 ligand) for 24 h, and then co-cultured with splenic
naı ¨ve CD4
+ T cells for 4 days. IL-10 production by re-stimulated
T cells was quantified by ELISA. Data are representative of two
independent experiments. Error bars, S.D. *P,0.01.
(PDF)
Figure S6 B. breve directly acts on CD103
+ DCs to
induce Tr1 cells. CD103
+ DCs were treated by B.breve or
culture supernatant (10-fold concentrated) of B. breve for 24 h.
After washing, naı ¨ve CD4
+ T cells were co-cultured with treated
CD103
+ DCs for 4 days. Then, T cells were harvested and re-
stimulated by anti-CD3 and anti-CD28 mAbs. IL-10 concentra-
tion in the supernatants was quantified by ELISA. Representative
data were shown from two independent experiments. Error bars,
S.D. N.D, not detected.
(PDF)
Figure S7 Induction of Tr1 cell development by killed B.
breve. CD103
+ DCs were treated by live, UV killed or sonicated
B. breve for 24 h, and then, co-cultured with naı ¨ve CD4
+ T cells for
4 days. T cells were harvested and re-stimulated by anti-CD3 and
anti-CD28 mAbs. IL-10 concentration in the supernatants was
quantified by ELISA. Data were representative of three indepen-
dent experiments. Error bars, S.D. *P,0.01, N.S, not significant.
(PDF)
Table S1 Composition of fecal commensal microflora
in probiotics-fed mice. 6-week-old C57BL/6 mice were fed
with L. casei, B. breve or placebo daily (1610
9) by oral gavage for 3
months (n=5, respectively). Fecal samples were collected, weighed
and suspended in 9 volumes of sterilized anaerobic transfer
medium. Total RNA and DNA fractions extracted from each
sample were assessed by RT-qPCR or qPCR with the specific
primers. ‘‘Number’’ indicates CFU of each bacteria calculated
using control cultured bacteria. (x/5) indicated the right side of
‘‘number’’ show detection rate of mice analyzed.
(PDF)
Text S1 Supplemental methods. Methods for ‘‘Analysis of
Fecal Microbiota’’ and ‘‘Culture and Killing of B. breve’’ are
described with references.
(PDF)
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